Abstract
1 Double-blind controlled comparisons of nomifensine with placebo, imipramine, desipramine, viloxazine, nortriptyline, a combination of amitriptyline and chlordiazepoxide, and diazepam have been carried out in various parts of the world.
2 Dosage ranged from 50-225 mg daily, and treatment lasted from 2-26 weeks.
3 Nomifensine was shown to possess useful antidepressive activity, to counteract inhibition, to restore drive and to relieve anxiety.
4 Adverse reactions were uncommon, particularly anticholinergic effects, and nomifensine was not shown to cause sedation or to interact with alcohol. No withdrawal phenomena were observed after 6 months' treatment.
5 Nomifensine is not suitable for severely agitated patients.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Acébal E., Subirá S., Spatz J., Faleni R., Merzbacher B., Gales A., Moizeszowicz J. A double blind comparative trial of nomifensin and desimipramine in depression. Relationship between treatment and phenylethylamine excretion. Eur J Clin Pharmacol. 1976 Jun 15;10(2):109–113. doi: 10.1007/BF00609468. [DOI] [PubMed] [Google Scholar]
- Angst J., Koukkou M., Bleuler-Herzog M., Martens H. Ergebnisse eines offenen und eines Doppelblindversuches von Nomifensin im Vergleich zu Imipramin. Arch Psychiatr Nervenkr (1970) 1974;219(3):265–276. doi: 10.1007/BF00342052. [DOI] [PubMed] [Google Scholar]
- Jenner F. A. Some of the problems and difficulties associated with clinical studies of antidepressant agents. Br J Clin Pharmacol. 1977;4(Suppl 2):199S–207S. doi: 10.1111/j.1365-2125.1977.tb05753.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moizeszowicz J., Subirá S. Controlled trial of nomifensin (HOE 984) and viloxazine in the treatment of depression in the elderly. J Clin Pharmacol. 1977 Jan;17(1):81–83. doi: 10.1002/j.1552-4604.1977.tb04589.x. [DOI] [PubMed] [Google Scholar]